Segment Information - Disaggregation of Revenue (Details) - USD ($)
$ in Millions |
3 Months Ended |
9 Months Ended |
Sep. 30, 2025 |
Sep. 30, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
| Disaggregation of Revenue |
|
|
|
|
| Total net revenues |
$ 15,776
|
$ 14,460
|
$ 44,542
|
$ 41,232
|
| All other |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
660
|
726
|
2,010
|
2,280
|
| Immunology | Skyrizi |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
4,708
|
3,205
|
12,556
|
7,940
|
| Immunology | Skyrizi | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
4,085
|
2,778
|
10,847
|
6,774
|
| Immunology | Skyrizi | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
623
|
427
|
1,709
|
1,166
|
| Immunology | Rinvoq |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
2,184
|
1,614
|
5,930
|
4,137
|
| Immunology | Rinvoq | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
1,559
|
1,170
|
4,231
|
2,912
|
| Immunology | Rinvoq | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
625
|
444
|
1,699
|
1,225
|
| Immunology | Humira |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
993
|
2,227
|
3,294
|
7,311
|
| Immunology | Humira | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
619
|
1,765
|
2,165
|
5,896
|
| Immunology | Humira | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
374
|
462
|
1,129
|
1,415
|
| Neuroscience | Vraylar |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
934
|
875
|
2,599
|
2,343
|
| Neuroscience | Vraylar | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
931
|
873
|
2,592
|
2,338
|
| Neuroscience | Vraylar | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
3
|
2
|
7
|
5
|
| Neuroscience | Botox Therapeutic |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
985
|
848
|
2,779
|
2,410
|
| Neuroscience | Botox Therapeutic | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
825
|
708
|
2,323
|
1,988
|
| Neuroscience | Botox Therapeutic | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
160
|
140
|
456
|
422
|
| Neuroscience | Ubrelvy |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
354
|
269
|
932
|
703
|
| Neuroscience | Ubrelvy | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
344
|
261
|
907
|
685
|
| Neuroscience | Ubrelvy | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
10
|
8
|
25
|
18
|
| Neuroscience | Qulipta |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
288
|
176
|
748
|
457
|
| Neuroscience | Qulipta | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
252
|
168
|
661
|
442
|
| Neuroscience | Qulipta | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
36
|
8
|
87
|
15
|
| Neuroscience | Vyalev |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
138
|
28
|
299
|
55
|
| Neuroscience | Vyalev | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
53
|
0
|
81
|
0
|
| Neuroscience | Vyalev | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
85
|
28
|
218
|
55
|
| Neuroscience | Duodopa |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
96
|
111
|
289
|
339
|
| Neuroscience | Duodopa | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
16
|
24
|
56
|
72
|
| Neuroscience | Duodopa | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
80
|
87
|
233
|
267
|
| Neuroscience | Other Neuroscience |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
46
|
56
|
160
|
183
|
| Neuroscience | Other Neuroscience | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
42
|
54
|
148
|
172
|
| Neuroscience | Other Neuroscience | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
4
|
2
|
12
|
11
|
| Oncology | Imbruvica |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
706
|
828
|
2,198
|
2,499
|
| Oncology | Imbruvica | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
507
|
618
|
1,579
|
1,823
|
| Oncology | Imbruvica | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Collaboration revenues |
$ 199
|
$ 210
|
$ 619
|
$ 676
|
| Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] |
Total net revenues
|
Total net revenues
|
Total net revenues
|
Total net revenues
|
| Oncology | Venclexta |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
$ 726
|
$ 677
|
$ 2,082
|
$ 1,928
|
| Oncology | Venclexta | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
341
|
340
|
974
|
921
|
| Oncology | Venclexta | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
385
|
337
|
1,108
|
1,007
|
| Oncology | Elahere |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
170
|
139
|
508
|
331
|
| Oncology | Elahere | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
150
|
139
|
453
|
331
|
| Oncology | Elahere | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
20
|
0
|
55
|
0
|
| Oncology | Epkinly |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
69
|
43
|
190
|
106
|
| Oncology | Epkinly | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Collaboration revenues |
$ 44
|
$ 31
|
$ 129
|
$ 82
|
| Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] |
Total net revenues
|
Total net revenues
|
Total net revenues
|
Total net revenues
|
| Oncology | Epkinly | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
$ 25
|
$ 12
|
$ 61
|
$ 24
|
| Oncology | Other Oncology | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
11
|
0
|
13
|
0
|
| Aesthetics | Botox Cosmetic |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
637
|
671
|
1,885
|
2,033
|
| Aesthetics | Botox Cosmetic | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
379
|
414
|
1,084
|
1,253
|
| Aesthetics | Botox Cosmetic | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
258
|
257
|
801
|
780
|
| Aesthetics | Juvederm Collection |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
253
|
258
|
744
|
898
|
| Aesthetics | Juvederm Collection | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
98
|
105
|
278
|
349
|
| Aesthetics | Juvederm Collection | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
155
|
153
|
466
|
549
|
| Aesthetics | Other Aesthetics |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
303
|
310
|
945
|
947
|
| Aesthetics | Other Aesthetics | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
265
|
272
|
817
|
828
|
| Aesthetics | Other Aesthetics | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
38
|
38
|
128
|
119
|
| Eye Care | Ozurdex |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
117
|
119
|
365
|
374
|
| Eye Care | Ozurdex | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
32
|
33
|
92
|
102
|
| Eye Care | Ozurdex | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
85
|
86
|
273
|
272
|
| Eye Care | Lumigan/Ganfort |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
97
|
116
|
306
|
310
|
| Eye Care | Lumigan/Ganfort | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
42
|
58
|
142
|
129
|
| Eye Care | Lumigan/Ganfort | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
55
|
58
|
164
|
181
|
| Eye Care | Alphagan/Combigan |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
47
|
62
|
143
|
170
|
| Eye Care | Alphagan/Combigan | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
9
|
26
|
35
|
54
|
| Eye Care | Alphagan/Combigan | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
38
|
36
|
108
|
116
|
| Eye Care | Other Eye Care |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
248
|
228
|
715
|
742
|
| Eye Care | Other Eye Care | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
138
|
123
|
399
|
421
|
| Eye Care | Other Eye Care | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
110
|
105
|
316
|
321
|
| Other Key Products | Mavyret |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
312
|
302
|
993
|
1,020
|
| Other Key Products | Mavyret | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
146
|
147
|
472
|
458
|
| Other Key Products | Mavyret | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
166
|
155
|
521
|
562
|
| Other Key Products | Creon | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
368
|
338
|
1,127
|
995
|
| Other Key Products | Linzess/Constella |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
326
|
234
|
732
|
721
|
| Other Key Products | Linzess/Constella | United States |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
315
|
225
|
701
|
693
|
| Other Key Products | Linzess/Constella | International |
|
|
|
|
| Disaggregation of Revenue |
|
|
|
|
| Net revenues |
$ 11
|
$ 9
|
$ 31
|
$ 28
|